Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial

James Wassil, Maggie Sisti, Jeff Fairman, Matthew Davis, Carlos Fierro, Sean Bennett, Derek R. Johnson, Thi‐Sau Migone, Kien T. Nguyen, Paul Sauer, Michelle Currie, Sam Iki, Jakub K. Simon